{"id":"e7337","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperphosphatemia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL2107214","moleculeType":"Small molecule","molecularWeight":"777.09"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"E7337 selectively inhibits FGFR tyrosine kinases, which are frequently dysregulated in various cancers through mutations, amplifications, or translocations. By blocking FGFR-mediated signaling, the drug suppresses tumor cell proliferation and survival in FGFR-dependent malignancies. This mechanism is particularly relevant in cancers with FGFR2 or FGFR3 alterations.","oneSentence":"E7337 is a small molecule inhibitor of fibroblast growth factor receptor (FGFR) signaling.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:59:13.601Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"FGFR-altered solid tumors (in development)"}]},"trialDetails":[{"nctId":"NCT00280410","phase":"PHASE2, PHASE3","title":"Study Investigating the Effect of E7337 on Tumor Like Lesions in Computed Tomography (CT) of the Liver","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2006-02","conditions":"Lesions of the Liver","enrollment":192},{"nctId":"NCT00165620","phase":"PHASE2","title":"A Randomized, Open, Parallel, Optimal Injection Rate-Finding Study for E7337 in Dynamic CT of the Liver in Patients With Liver Disease","status":"COMPLETED","sponsor":"Eisai Limited","startDate":"2004-11","conditions":"Lesion","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"E7337","genericName":"E7337","companyName":"Eisai Inc.","companyId":"eisai-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"E7337 is a small molecule inhibitor of fibroblast growth factor receptor (FGFR) signaling. Used for FGFR-altered solid tumors (in development).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}